Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | SOD1 | P00441 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291606 | 0.94 | SCN9A (0.38) | SCN9ASCN10ARBP4TACR1 | |
| SCHEMBL4750064 | 0.85 | CA1 (0.36) | SCN9ASOD1 | |
| SCHEMBL4291240 | 0.85 | CA1 (0.36) | SCN9ASOD1 | |
| SCHEMBL13705345 | 0.84 | CXCR4 (0.41) | SCN9ATACR1KDM4EALDH1A1LMNA | |
| SCHEMBL3493396 | 0.81 | TEAD1 (0.46) | KDM4EALDH1A1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL4293711 | 0.80 | PARP1 (0.45) | KDM4EALDH1A1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL4293709 | 0.80 | PARP1 (0.45) | KDM4EALDH1A1GAAKMT2A | |
| SCHEMBL4290773 | 0.80 | KMT2A (0.46) | KDM4EALDH1A1HTTKMT2A | |
| SCHEMBL13705346 | 0.79 | CXCR4 (0.40) | KDM4EALDH1A1LMNAGAAHTT | |
| SCHEMBL4281389 | 0.78 | RBP4 (0.38) | RBP4TACR1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | SCN9A 1866/4885SCN10A 2828/4885RBP4 2468/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | SCN9A 1866/4885SCN10A 2828/4885RBP4 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.